You are here: Industry Insights > Baricitinib

News List

Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018 americanpharmaceuticalreview
August 31, 2017
Eli Lilly and Incyte announced that Lilly will resubmit the New Drug Application (NDA) for baricitinib before the end of January 2018. Baricitinib is a once-daily oral investigational medication for the treatment of patients with moderate-to-severe rheuma
Lilly and Incyte Provide Update on Baricitinib lilly
July 26, 2017
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib will be delayed beyond 2017.
NICE recommends Lilly’s Baricitinib (Olumiant) to treat rheumatoid arthritis europeanpharmaceuticalreview
July 05, 2017
Baricitinib is the first JAK inhibitor to be recommended by NICE to treat rheumatoid arthritis in adults who have not responded to conventional therapy…
EC approves Eli Lilly’s rheumatoid arthritis drug europeanpharmaceuticalreview
February 17, 2017
The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA)。
Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show bari Lilly
February 16, 2017
Eli Lilly and Company and Incyte Corporation announced today additional detailed results from RA-BEAM - a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) - were published in the New England Journal of
FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment americanpharmaceuticalreview
January 18, 2017
Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment
U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment lilly
January 16, 2017
Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib.

Previous page 1 2 3 4 5 Next page